GATA1 and oral cavity squamous cell carcinoma: Recently, a pivotal study indicated that miR-876-3p antogomir, packaged and delivered by sEVs derived from CAFs, can target GATA-binding protein 1 (GATA1) and reduce cisplatin resistance in Oral squamous cell carcinoma (OSCC) cells.